Abstract
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %
| Original language | English |
|---|---|
| Pages (from-to) | 3037-3042 |
| Number of pages | 6 |
| Journal | Clinical Cancer Research |
| Volume | 12 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - May 15 2006 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. / Iacobucci, Ilaria; Saglio, Giuseppe; Rosti, Gianantonio; Testoni, Nicoletta; Pane, Fabrizio; Amabile, Marilina; Poerio, Angela; Soverini, Simona; Bassi, Simona; Cilloni, Daniela; Bassan, Renato; Breccia, Massimo; Lauria, Francesco; Izzo, Barbara; Merante, Serena; Frassoni, Francesco; Paolini, Stefania; Montefusco, Enrico; Baccarani, Michele; Martinelli, Giovanni.
In: Clinical Cancer Research, Vol. 12, No. 10, 15.05.2006, p. 3037-3042.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
AU - Iacobucci, Ilaria
AU - Saglio, Giuseppe
AU - Rosti, Gianantonio
AU - Testoni, Nicoletta
AU - Pane, Fabrizio
AU - Amabile, Marilina
AU - Poerio, Angela
AU - Soverini, Simona
AU - Bassi, Simona
AU - Cilloni, Daniela
AU - Bassan, Renato
AU - Breccia, Massimo
AU - Lauria, Francesco
AU - Izzo, Barbara
AU - Merante, Serena
AU - Frassoni, Francesco
AU - Paolini, Stefania
AU - Montefusco, Enrico
AU - Baccarani, Michele
AU - Martinelli, Giovanni
PY - 2006/5/15
Y1 - 2006/5/15
N2 - Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %
AB - Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %
UR - http://www.scopus.com/inward/record.url?scp=33744798191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33744798191&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-2574
DO - 10.1158/1078-0432.CCR-05-2574
M3 - Article
C2 - 16707599
AN - SCOPUS:33744798191
VL - 12
SP - 3037
EP - 3042
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 10
ER -